As usual, your propagandists have kept you ignorant of the policies Biden enacted to lower prescription drug costs.
And how did Trump react as soon as he got the chance?
On his first day in office, President Trump signed dozens of executive orders rolling back key initiatives from the Biden Administration. The topics covered in Trump’s orders ranged from future pandemic preparedness to withdrawing the United States from the Paris Climate Agreement. One action that created some confusion among consumers was the rescission of Biden’s Executive Order 14087, Lowering Prescription Drug Costs for American
Biden’s 2022 order instructed the federal Department of Health and Human Services to “select for testing by the Innovation Center new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid programs, including models that may lead to lower cost-sharing for commonly used drugs and support value-based payment that promotes high-quality care.”
In other words, the Center for Medicare and Medicaid Innovation (CMMI) would test different ways to lower the cost of prescription drugs for older adults, including one model that would have capped the price of generic medications at $2 per month.
President Donald J. Trump’s second-term health care agenda is taking shape with a clear focus on undoing several Biden-era policies.1 On Inauguration Day, January 20, 2025, Trump signed an executive order reversing initiatives aimed at reducing prescription drug costs for Medicare and Medicaid recipients, expanding the Affordable Care Act (ACA), and increasing protections for Medicaid enrollees.
Trump's EO is completely unenforceable.
Also, this from the EO:
(iii) following the report issued under section 13 of Executive Order 14273 of April 15, 2025 (Lowering Drug Prices by Once Again Putting Americans First), the Attorney General and the Chairman of the Federal Trade Commission shall, to the extent consistent with law, undertake enforcement action against any anti-competitive practices identified within such report, including through use of sections 1 and 2 of the Sherman Antitrust Act and section 5 of the Federal Trade Commission Act, as appropriate;
Someone needs to sit these retards down and explain patent law to them.
And then there is this:
(ii) the Secretary shall consider certification to the Congress that importation under section 804(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) will pose no additional risk to the public’s health and safety and result in a significant reduction in the cost of prescription drugs to the American consumer; and if the Secretary so certifies, then the Commissioner of Food and Drugs shall take action under section 804(j)(2)(B) of the FDCA to describe circumstances under which waivers will be consistently granted to import prescription drugs on a case-by-case basis from developed nations with low-cost prescription drugs;
Every once in a while, some numbnut talks about importing cheap prescription drugs from Canada.
They never look at the population demographics. We have more people over the age of 65 than Canada's entire population.
Never gonna happen.
mxmnews.com
